Glaucoma surgical device lowers IOP level

Digital EditionOphthalmology Times: January 2023
Volume 48
Issue 1

Minimally invasive, novel system achieves significant pressure level reductions.

The surgical device is an FDA-cleared instrument for delivering small volumes of ophthalmic viscoelastic during ocular surgery

The surgical device is an FDA-cleared instrument for delivering small volumes of ophthalmic viscoelastic during ocular surgery

Reviewed by Gabriel Lazcano-Gomez, MD

A minimally invasive glaucoma surgical device called the STREAMLINE surgical System from New World Medical, Inc successfully lowered intraocular pressure (IOP) level and demonstrated a good short-term safety profile, according to Gabriel Lazcano-Gomez, MD, who reported 3-month interim results with the device. Lazcano-Gomez is in private practice in Puebla, Mexico.

The surgical device is an FDA-cleared instrument for delivering small volumes of ophthalmic viscoelastic during ocular surgery. The single-use, disposable instrument consists of a polymer handset tipped with a surgical stainless steel cannula with a long, thin neck that accesses the trabecular meshwork through a clear corneal incision. An actuator button on the handset, when depressed, retracts a polymer outer sleeve from a stainless steel inner cutting cannula tip and delivers viscoelastic, facilitating transluminal dilation over several hours.

First-in-human study

A prospective first-in-human interim analysis evaluated the surgical system in a study that included 52 eyes at 3 surgical sites. In this study, the device was used following phacoemulsification in patients with mild to moderate open-angle glaucoma (OAG) and postwashout IOP level of 22 to 34 mmHg. After the cataract procedure, the surgical procedure was performed in 1 eye. Using a surgical gonioscope, 5 applications of viscoelastic were injected into the Schlemm canal, Lazcano-Gomez explained.

The investigators collected data on IOP levels, medications, and surgical complications. The patients were followed postoperatively on day 1, week 1, and months 1 and 3.

Lazcano-Gomez reported that the average IOP level decreased significantly at each follow-up visit. Decrease in IOP level ranged from 5.5 to 8 mmHg. At month 3, the IOP level decreased by an average of 34.2% (P<.05) compared with baseline. The average number of glaucoma medications used also decreased significantly (P<.05), from 2.1 medications during the screening visit to 0.8 medications at month 3. A transient IOP level spike between week 1 and month 1 experienced by 1 patient resolved with topical treatment.

Lazcano-Gomez said he believes the device has a promising future. “The Streamline Surgical System successfully lowered the IOP [level] when used to perform transluminal dilation of Schlemm canal [when] combined with phacoemulsification in eyes with mild to moderate OAG,” Lazcano-Gomez explained. “The procedure was associated with decreased dependence on IOP [level]–lowering medications and had a favorable safety profile similar to other minimally invasive glaucoma surgical techniques.”

Gabriel Lazcano-Gomez, MD
E: drlazcano.glaucoma@gmail.com
Lazcano-Gomez is a consultant to New World Medical, Inc.

Related Videos
ViaLase seeks to disrupt glaucoma treatment paradigm with new femtosecond laser treatment
Contralateral eye study investigates iStent vs Hydrus stent for glaucoma
Robot-assisted micro interventional glaucoma surgery reduces surgeon's tremors
Related Content
© 2023 MJH Life Sciences

All rights reserved.